Edwards Lifesciences (EW) Raises Full-Year Forecast Post Strong Q2 Earnings Stock up 5.5%

by MarketNewsData

Q2 2025 Earnings – Reported July 24, 2025

Edwards Lifesciences posted strong second-quarter results, exceeding expectations on both the top and bottom lines and lifting its 2025 sales and earnings guidance. The stock rose 5.54% to close at $80.00 on July 25.

Earnings Snapshot

  • Adjusted EPS: $0.67
    ▲ Beat estimate of $0.62
  • Revenue: $1.53 billion
    ▲ Up 11.9% YoY, beat estimate of $1.49 billion

Guidance Update

  • FY2025 Sales Growth: Raised to 9–10% (prior: 8–9%)
  • FY2025 Adjusted EPS: Now seen at the upper end of $2.40–$2.50
  • Q3 2025 Revenue: Expected between $1.46B–$1.54B
  • Q3 2025 Adjusted EPS: Range of $0.54–$0.60

Business Highlights

  • TAVR segment: Sales growth outlook increased to 6–7%
  • New approvals:
    • SAPIEN platform approved in U.S. and EU for asymptomatic patients
    • CE Mark granted for SAPIEN M3 system

Stock Reaction – July 25, 2025

  • Open: $81.50
  • High: $83.00
  • Low: $77.52
  • Close: $80.00
  • Change: +$4.20 (+5.54%)
  • Volume: 15.66M shares

Takeaway

Strong execution across all product lines, favorable regulatory momentum, and an upwardly revised outlook helped drive investor confidence. Edwards is positioning for sustained growth in structural heart therapies.

More Live News